Eli Lilly: A Calculated Risk?

by

Right. Eli Lilly. A trillion-dollar healthcare play. Sounds…ambitious, doesn’t it? And frankly, a bit terrifying. The stock’s had a wobble, down around 19% from its peak. People are getting twitchy. Valuation concerns, whispers about competition… honestly, it’s all a bit predictable. But here’s the thing: I’ve been staring at these numbers, and ignoring the gut-level panic is proving… profitable. So, let’s talk about it. Because if you’re looking for a straight answer, you’ve come to the wrong place. This isn’t about certainty; it’s about assessing the mess, and seeing if we can make some money from it.

The Expanding Anti-Obesity Market

Okay, so everyone’s fixated on the weight-loss drugs. And rightly so. It’s a booming market, and Eli Lilly is, for the moment, leading the charge. There will be competition, obviously. There always is. But they’ve got a head start, and they’re not resting on their laurels. Orforglipron, an oral GLP-1… sounds like something out of a sci-fi film, doesn’t it? But apparently, it’s a game-changer. The fact that it’s an oral medication is… significant. People are less keen on injections, generally. It’s a convenience thing, but it matters. They’re learning from Wegovy, which, let’s be honest, isn’t exactly subtle.

And then there’s retatrutide. Honestly, the clinical trial results are… almost unbelievable. 28.7% weight loss? And reduced knee pain? It’s like they’ve stumbled upon the fountain of youth, or at least a very effective way to avoid hip replacements. They’re targeting people with higher BMIs, which is smart. Because let’s face it, those are the patients who really need it, and who are likely to stick with the treatment. It’s a cynical observation, but a true one.

Loading widget...

Beyond Weight Management

But what if the weight-loss market doesn’t explode like everyone expects? What if it plateaus? It’s a valid concern. Which is why I’m looking at Eli Lilly’s broader portfolio. They’re not putting all their eggs in one basket, which is… refreshing. Novo Nordisk, their biggest rival, is a bit more focused, shall we say. Eli Lilly has Verzenio, a cancer drug, bringing in a tidy $5.7 billion last year. And Taltz, an immunosuppressant, chipping in another $3.6 billion. It’s not the same scale as their diabetes and obesity products, obviously, but it provides a buffer. A safety net. And I like safety nets. Especially in this market.

They’re also aggressively expanding their pipeline, acquiring new candidates, exploring different fields. Pain management, oncology, immunology… it’s a bit of a scattergun approach, but it shows ambition. And frankly, a bit of desperation. Which, again, I find… relatable. They’re throwing everything at the wall to see what sticks. And sometimes, that’s all you can do.

Now, the stock trades at 27x forward earnings, which is a premium. Is it justified? Look, it’s not cheap. But they’re growing faster than their peers, and they have a deep pipeline that should continue to drive growth. So, yes, I think it is. Is it a sure thing? Absolutely not. Nothing is. But right now, it looks… attractive. Like a slightly reckless, but potentially rewarding, gamble. And sometimes, that’s exactly what you need.

Read More

2026-03-22 01:32